spn report on india today
TRANSCRIPT
India
Today……….
Compiled by:CK Shah
Client Confidential
Shresth Pharma Nexus(SPN) is a businessconsulting company active within the fieldof Pharmaceuticals and Health Care. Itspecialises in providing a Global network toits customers, allowing them to choose fromthe best in the market. The idea is to bringthe market to the customer, providing themsolutions and making business an easy task.We work with organizations in the arena ofstrategic management, which requires adistinctive approach from operationalmanagement.
Client Confidential
Our key role is to build the road to your prosperity:
We Lay Foundation for Future GrowthClient Confidential
Range of Services
Business Consultancy
For Merger, Acquisition
& Disposal
Strategic tie-ups
Project Evaluation
CRAMs & Analytical
Services
Registration of API/FF
With DCGI, India
Enterprise Risk
Management
Market Assessment
& Intelligence
Business plan review
Organizational review
Shresth Pharma Nexus
Client Confidential
What We Offer
API Manufacturer
Sourcing Intermediates from India/China
Sales & Marketing
Custom Synthesis
Technology
Turn Key Projects
Finished Formulation
Manufacturer
Sourcing of API
In & Out Licensing
CRAMs
Generic NDDS, Formulation dossier
Whole chain of analytical services.
Client Confidential
Our PhilosophyWe comprehend our customers’ needsaccurately and provide them with bestbusiness alternatives, as we believe thatbusiness should always be customer driven.However, we offer more than mere business.We help you make relations and partnershipthat lead towards triumph. We giveimportance to confidentiality andtransparency in our business. And that is ourmotive to deliver, with honesty and trust.Our key role is to build the road to yourprosperity.
“We Lay Foundation for
Future Growth”Client Confidential
India
Today……….
Client Confidential
Projected Growth ofIndian Pharmaceutical Market
Currently
• Total Worth $19billion– Domestic Market: $11bn
– Exports: $8bn
• Ranked 14th in World
Forecasted Growth for 2020
• Increase to $50billion– Domestic Market: $30bn
– Exports: $20bn
• Will be one of top 10 markets
Source: PwC, Global pharma looks to India: Prospects for growth
Client Confidential
India is expected to be the 7th largest market by 2020
Top Pharma Markets 2015* & 2020 (US$ bn)
However, among all Top 10 global markets of 2015 India shows the highest growth rate among all countries analysed by McKinsey
Source: BCG, Goldman Sachs, McKinsey Reports
Client Confidential
Global API Manufacturer
Source: TR Newport Premium™ Client Confidential
Local
PotentialFuture
LessEstablished
Established
Companies serving their local markets. Lack quality, regulatory, experience to supply major markets
Companies usually make older molecules, may supply intermediates to Established companies, often working to upgrade & forge links with dose firms in major markets
Meet regulatory, quality, & other criteria for limited number of molecules. May be moving from older to new molecules, may supply intermediates to Established companies.
Leading companies with business experience, regulatory, quality, non-infringing processes, and track record of supplying regulated markets
Able to satisfy local markets Global markets
Unregulated cGMP, FDA Inspected
Older molecules New molecules
Assessing the Capabilities ofAPI Manufacturers
Client Confidential
Global API Manufacturer rated
Source: TR Newport Premium™ Client Confidential
API manufacturer-Emerging markets
Source: TR Newport Premium™
Client Confidential
2nd wave emerging API manufacturers rated
Source: TR Newport Premium™Client Confidential
India’s API Plants
Client Confidential
Indian API Manufacturer Ratings 2004 to 2010
1817
56
24
40
92
0
10
20
30
40
50
60
70
80
90
100
Established Less Established Potential Future
Nu
mb
er
of
Co
rpo
rate
Gro
up
s
Corporate API Rating Assessed by Thomson Reuters
2004
2010
Source: Newport Premium™ Client Confidential
Local
PotentialFuture
LessEstablished
Established
Able to satisfy local markets Global markets
Unregulated cGMP, FDA Inspected
Older molecules New molecules
Capabilities ofIndian API Manufacturers
24 corporate groups, 34 API sitese.g., Cipla, Dr. Reddy’s
40 corporate groups, 47 API sitese.g., MSN, Hetero
92 corporate groups, 91 API sitese.g., Emcure, Sai Advantium
480 corporate groups, 492 API sitese.g., SMILAX Laboratories
Client Confidential
Comparing the Ability of Indian and Chinese Manufacturers to Supply
Regulated Markets
Source: Newport Premium™
24
40
92
12
34
150
0
20
40
60
80
100
120
140
160
Established Less Established Potential Future
Nu
mb
er
of
Co
rpo
rate
Gro
up
s
Corporate Rating Assessed by Thomson Reuters
India
China
Client Confidential
DMFs & COS by India & China
Client Confidential
Year wise US DMFs Submitted by India & China
23
31
44
63
114
184
257
283
331
382
350
5
15
5
25
35
33
52
64
122
119
94
0 100 200 300 400
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Number of US DMFs
China
India
Source: Newport Premium™
Client Confidential
COSs Granted 2000 to 2009 to India, Italy, China & ROW (includes US)
2000 2009
Source: Newport Premium™
India24%
China 10%
Italy12%
ROW54%
459 COS 2722 COS
Client Confidential
US ANDAs Held by Indian Companies
Source: Newport Premium™
210 14 12 18
42
63
117
147139
38
0
10
19
21
17 29
11
0
20
40
60
80
100
120
140
160
180
Nu
mb
er
of
US
AN
DA
s
Year
Tentative
Approved
Client Confidential
Increase in Indian Holders of US ANDAs
210
14 1218
52
82
138
164168
49
0
5
10
15
20
25
30
0
20
40
60
80
100
120
140
160
180
Nu
mb
er
of
Ind
ia B
ase
d A
ND
A H
old
ers
Nu
mb
er
US
AN
DA
s
by I
nd
ian
Co
mp
an
ies
Source: Newport Premium™
Client Confidential
Top Ten Paragraph IV Challengers by Volume
149
75 72
57 55
42 3932 30 27
0
20
40
60
80
100
120
140
160
Nu
mb
er
of
PIV
C
ha
lle
ng
es
Source: Newport Premium™
Client Confidential
Innovation
1
11
6
5
1
4
4
0
7
4
3
12
6
0
4
2
3
0
1
1
0
0
2
0
1
4
0
2
1
4
0
2
1
2
2
2
1
1
1
0
1
1
0
0
1
0
0
1
1
0
0
1
0
1
0
0
0
0
0
2
1
1
0
0
0
0 5 10 15 20
Ipca Laboratories
Dr Reddy's
Ranbaxy [now Daiichi Sankyo]
Glenmark
Nicholas Piramal
Wockhardt
Torrent
Jubilant Organosys
Biocon
Lupin
Sun Pharma
Orchid
Zydus Cadila
Number of Compounds
Pre-Clinical
Phase I
Phase II
Phase III
Review
Source: Newport Premium Deals Module™Client Confidential
Acquisitions by Foreign Companies of Indian Targets
38
4547
43 42
65
72
56
68
76
0
10
20
30
40
50
60
70
80
Nu
mb
er
of
Ac
qu
isit
ion
s
Year
Source: Newport Premium Deals Module™Client Confidential
Significant Foreign Acquisitions ofIndian Companies
Mylan’s acquisition of Matrix (2006)
Daiichi’s acquisition of Ranbaxy (2008)
Hospira’s acquisition of Orchid’s injectable business (2009)
Abbott’s acquisition of Piramal’s Healthcare Solutions Business (2010)
Source: Company websites
Client Confidential
Indian Acquisitions of Foreign Companies
Sun acquired Caraco (2004) & ICN Hungary (2005)
Dr Reddys acquired Betapharm Arzneimittel GmbH (2006)
Strides acquired Diaspa SpA (2007)
Lupin acquired Kyowa Pharmaceutical Industry co Ltd (2007)
Dishman acquired Solvay Pharmaceuticals BV - Fine Chemical & Vitamin Business (2007)
Sun acquired Chattem’s controlled substance facility (2008)
Piramal acquired Minrad International (2008)
Source: Company websites
Client Confidential
Biotech Capabilities Among Top Indians
Company RecombinantProteins
Monoclonal Antibodies
Vaccines Launches
Biocon FP FP EPO, MAb
Shantha FP UD INF, GCSF
Intas FP UD GCSF, INF, EPO
Panacea FP Vaccines
Lupin FP
Zydus FP FP
Torrent FP Insulin
Wockhardt FP UD Insulin, INF, CGSF, EPO
Glenmark UD FP Novel only
Bharat UD FP
Shasun FP
Source: TR Research Key: FP = Full Production, UD = Under DevelopmentClient Confidential
